Pfizer Gets CDSCO Panel Nod To Import 20 Valent Pneumococcal Conjugate Vaccine

New Delhi: Pfizer has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to import the 20-Valent Pneumococcal Conjugate Vaccine (20vPnC).

This came after the vaccine major Pfizer presented the global immunogenicity data of all subjects vis-à-vis immunogenicity data of Indian subjects for 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) and the immunogenicity data of Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) I.P. 13 valent.

The pneumococcal 20-valent conjugate vaccine is an active immunizing agent used to prevent infection caused by certain types of pneumococcal bacteria (Streptococcus pneumoniae).

Pneumococcal bacteria are one of the most common causes of pneumonia. Pneumococcal conjugate vaccine can prevent pneumococcal disease. Pneumococcal disease refers to any illness caused by pneumococcal bacteria. These bacteria can cause many types of illnesses, including pneumonia, which is an infection of the lungs.

At the recent SEC meeting for Vaccine held on 26th November 2024, the expert panel reviewed the global immunogenicity data of all subjects vis-à-vis immunogenicity data of Indian subjects for the 20-valent Pneumococcal Conjugate Vaccine (20vPnC) and the immunogenicity data of the pneumococcal polysaccharide conjugate Vaccine (Adsorbed) I.P. 13 valent

After detailed deliberation and based on the data presented, the committee noted the results and recommended the grant of import permission of 20-Valent Pneumococcal Conjugate Vaccine (20vPnC).

Also Read: Abbott Healthcare Gets CDSCO Panel Nod To Manufacture Market Ursodeoxycholic acid for Obstetric Cholestasis